Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma

Journal of Clinical Oncology

Volumn 32, Issue 32, 2014, Pages 3659-3666

  Ott, Patrick A ^a   Hamid, Omid ^b   Pavlick, Anna C ^a   Kluger, Harriet ^c   Kim, Kevin B ^d   Boasberg, Peter D ^b   Simantov, Ronit ^e   Crowley, Elizabeth ^e   Green, Jennifer A ^e   Hawthorne, Thomas ^e   Davis, Thomas A ^e   Sznol, Mario ^c   Hwu, Patrick ^d  

^a NEW YORK UNIVERSITY   (United States)

^b Angeles Clinic and Research Institute   (United States)

^c YALE CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e Celldex Therapeutics Inc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GLEMBATUMUMAB VEDOTIN; GLYCOPROTEIN; GLYCOPROTEIN NMB; IMMUNOMODULATING AGENT; INTERLEUKIN 2; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; MONOCLONAL ANTIBODY;

ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOPULMONARY ARREST; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSGEUSIA; DYSPNEA; ERYTHEMA; ERYTHEMA MULTIFORME; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOTENSION; IMMUNOGENICITY; LEUKOPENIA; LIMB PAIN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL SEPSIS; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SEPSIS; SKIN EXFOLIATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RASH; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALOPECIA; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXANTHEMA; FATIGUE; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MELANOMA; MIDDLE AGED; NEUTROPENIA; TREATMENT OUTCOME;

EID: 84911933928     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.8115     Document Type: Article

References (44)

1. Brahmer JR, Tykodi SS, Chow LQ, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455-2465, 2012
2. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
3. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
4. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114, 2012
5. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
6. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
7. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
8. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
9. Weterman MA, Ajubi N, Van Dinter IM, et al: Nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer 60:73-81, 1995
10. Tse KF, Jeffers M, Pollack VA, et al: CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 12:1373-1382, 2006
11. Shikano S, Bonkobara M, Zukas PK, et al: Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem 276:8125-8134, 2001
12. Ripoll VM, Irvine KM, Ravasi T, et al: Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol 178:6557-6566, 2007
13. Selim AA, Abdelmagid SM, Kanaan RA, et al: Anti-osteoactivin antibody inhibits osteoblast differentiation and function in vitro. Crit Rev Eukaryot Gene Expr 13:265-275, 2003
14. Sheng MH, Wergedal JE, Mohan S, et al: Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity. FEBS Lett 582:1451-1458, 2008
15. Rose AA, Grosset AA, Dong Z, et al: Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 16:2147-2156, 2010
16. Kuan CT, Wakiya K, Dowell JM, et al: Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 12:1970-1982, 2006
17. Rose AA, Pepin F, Russo C, et al: Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 5:1001-1014, 2007
18. Rich JN, Shi Q, Hjelmeland M, et al: Bonerelated genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 278:15951-15957, 2003
19. Onaga M, Ido A, Hasuike S, et al: Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells. J Hepatol 39:779-785, 2003
20. Rose AA, Annis MG, Dong Z, et al: ADAM10 releases a soluble form of the GPNMB/osteoactivin extracellular domain with angiogenic properties. PLoS One 5:e12093, 2010
21. Doronina SO, Toki BE, Torgov MY, et al: Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778-784, 2003
22. Doronina SO, Bovee TD, Meyer DW, et al: Novel peptide linkers for highly potent antibodyauristatin conjugate. Bioconjug Chem 19:1960-1963, 2008
23. McDonagh CF, Turcott E, Westendorf L, et al: Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 19:299-307, 2006
24. Pollack VA, Alvarez E, Tse KF, et al: Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 60:423-435, 2007
25. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
26. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
27. De George JJ, Ahn CH, Andrews PA, et al: Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 41:173-185, 1998
28. Li YN, Zhang L, Li XL, et al: Glycoprotein nonmetastatic B as a prognostic indicator in small cell lung cancer. APMIS 122:140-146, 2014
29. Tanaka H, Shimazawa M, Kimura M, et al: The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis. Sci Rep 2:573, 2012
30. Burris HA III, Rugo HS, Vukelja SJ, et al: Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398-405, 2011
31. Krop IE, Lorusso P, Miller KD, et al: A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30:3234-3241, 2012
32. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821, 2010
33. Williams MD, Esmaeli B, Soheili A, et al: GPNMB expression in uveal melanoma: A potential for targeted therapy. Melanoma Res 20:184-190, 2010
34. Tomihari M, Hwang SH, Chung JS, et al: Gpnmb is a melanosome-associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD-dependent fashion. Exp Dermatol 18:586-595, 2009
35. Pahl MV, Vaziri ND, Yuan J, et al: Upregulation of monocyte/macrophage HGFIN (Gpnmb/osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol 5:56-61, 2010
36. Chung JS, Sato K, Dougherty II, et al: DC-HIL is a negative regulator of T lymphocyte activation. Blood 109:4320-4327, 2007
37. Chung JS, Dougherty I, Cruz PD, Jr, et al: Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol 179:5778-5784, 2007
38. Tomihari M, Chung JS, Akiyoshi H, et al: DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumorreactive T cells Cancer Res 70:5778-5787, 2010
39. Chung JS, Cruz PD, Jr, Ariizumi K: Inhibition of T-cell activation by syndecan-4 is mediated by CD148 through protein tyrosine phosphatase activity. Eur J Immunol 41:1794-1799, 2011
40. Yardley D, Weaver R, Melisko M, et al: A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study. Cancer Res 72:543s, 2012(suppl; abstr P6-10-01)
41. Rose AAN, Siegel PM: B-raf/Mek/Erk pathway inhibition induces GPNMB expression and sensitizes melanoma cells to the antibody-drug conjugate glembatumumab vedotin. Mol Cancer Ther 12:C232, 2013
42. Qian X, Mills E, Torgov M, et al: Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol Oncol 2:81-93, 2008
43. Lesterhuis WJ, Salmons J, Nowak AK, et al: Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One 8:e61895, 2013
44. Hiniker SM, Chen DS, Reddy S, et al: A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 5:404-407, 2012